With 41 biosimilars launched for 11 branded reference products, and at least 10 more expected to enter the market in 2025—plus dozens of others in the pipeline—pharmacies need a standardized approach for adding new biosimilars to their formularies, an expert noted during the 2024 NASP Annual Meeting & Expo, in Nashville, Tenn.
Sarah Yelenich, PharmD, CSP, a clinical services manager at the University of Arkansas for Medical Sciences Specialty Pharmacy, in Little Rock,